BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (August 2015)

23 slides from BioSpecifics Technologies's investor presentation, Aug 12, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE ps, . BioSpecifics August 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: BioSpecifics is a profitable, commercial-stage biopharma company

    BioSpecifics is a profitable, commercial-stage biopharma company receiving increasing revenues from sales of collagenase clostridium histolyticum or CCH (XIAFLEX®) by partner Endo with future revenue growth opportunities emerging from commitment to clinical development of new potential indications f

  4. Slide 4: Unlocking Vast Potential of CCH

    Unlocking Vast Potential of CCH First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture* Frozen shoulder Scarred tendons Peyron

  5. Slide 5: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture First and Only FDA- and EMA-Approved Nonsurgical Treatment Collagen cord in hand causing one or more fingers to contract toward the palm » Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Definition & Key Complications Post

  6. Slide 6: Commercial Highlights for DC

    Commercial Highlights for DC ~6,200 vials were shipped April 1, 2015 through June 30, 2015 Compared to 5,092 in 2Q14 Approved in Japan in July 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 MULTICORD U.S. label expansion approved in October 2014 Treatment of u

  7. Slide 7: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease First and Only FDA- and EMA-Approved Nonsurgical Treatment Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable Definition & plaque, penile deformity and ere

  8. Slide 8: Commercial Highlights for PD

    Commercial Highlights for PD ~6,900 vials were shipped April 1, 2015 through June 30, 2015 Compared to 2,752 in 2Q14 Continued traction with certified physicians and new patients in Peyronie’s disease As of June 30, 2015 there were ~2,100 certified physicians and ~9,800 cumulative patients enrolled

  9. Slide 9: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Future Revenue-Generating Opportunities Frozen Shoulder Phase 2b to initiate by end of 2015 Syndrome Cellulite Phase 2b to initiate by end of 2015 *Human - Lipoma Phase 2 top-line results 1H16 Canine Endo has li irther devel jt liporna indo has license for further developme

  10. Slide 10: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can Potential to be : require

  11. Slide 11: Phase 2b Study of CCH in Frozen Shoulder

    Phase 2b Study of CCH in Frozen Shoulder Study Design Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Objective & Rationale Phase 2b study based on positive, statistically significant results in Phase 2a study of 5

  12. Slide 12: Phase 2b Study Results of CCH in FSS

    Phase 2b Study Results of CCH in FSS Phase 2a Results Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar CCH patient improvement in pain seen across both trials Degree improvement

  13. Slide 13: CCH for Cellulite

    CCH for Cellulite Phase 2b Trial to Initiate by End of 2015 5 Skin dimpling as a result of collagen fibrous septae, occurring mainly Definition on the buttocks, lower limbs, and abdomen Significant Market Opportunity as First Nonsurgical Therapy Affects 85-98% of women (est.) and rarely in men Poten

  14. Slide 14: CCH for Cellulite

    CCH for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatme

  15. Slide 15: CCH for Human Lipomas

    CCH for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges Benn ition under the skin Potential to be No FDA-approved pharmaceutical therapies available Only Approved ; ; . — Nonsurgical Therapy Surgery not practical for patient

  16. Slide 16: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Reported in January 2014 Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of comme

  17. Slide 17: CCH for Lipomas in Canines

    CCH for Lipomas in Canines Lipomas can seriously restrict motion in older dogs Key Complications Surgery can be risky due to the use of general anesthesia - especially for older dogs Potential to be 1.7M dogs affected in the U.S. annually Only Approved Based on a survey of 77 participants, an averag

  18. Slide 18: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Endo Encouraged by Results Reported to Date Definition & Pain, decreased fertility, miscarriage, heavy menstrual = Key Complications bleeding and frequent urination i Potential to be Primary indication for 025 050 1.00 200 Nonsurgical Therapy hysterectomy in U.S. (33% to Sos

  19. Slide 19: Endo Partnership for Development and Commercialization of CCH

    Endo Partnership for Development and Commercialization of CCH >$62.9M Received $62.9M received in licensing, sublicensing, milestone, COGS, and to Date royalty payments as of June 30, 2015 Low double digit royalties as % of net sales purture Eavments Additional mark-up on COGS Due to BioSpecifics u

  20. Slide 20: Corporate Highlights

    Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications » Strong IP portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Drug product composition patent until 2028 and Biologic Exclusiv

  21. Slide 21: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the six months ended 06/30/15 06/30/14 Cash and equivalents, and investments $29,230,046 $16,633,708 Income Statement Revenues $10,321,429 $5,399,657 Other income 36,835, 29,600 Costs and expenses (4,094,588) (3,405,855) Provision

  22. Slide 22: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Upcoming Milestones *Human Lipomas OPhase 2 placebo-controlled opt-in trial top-line results in 1H16 *Uterine Fibroids Peyronie’s Disease Q Building sales momentum in the EU Q Refining development plan D n’s Conus Q Commercial launch in Japan Frozen Shoulder Initiate

  23. Slide 23: Innovators in the development & commercialization of injectable collagenase

    ° \4 Innovators in the development & commercialization of INJECTABLE COLLAGENASE —_—— . BioSpecifics August 2015

Biospecifics Technologies — Investor Presentation (August 2015) on 6ix